Geron Corporation

Award Value
Targeted Clinical Development: Jane Lebkowski Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury $6,405,771
Disease Team Therapy Planning I: Jane Lebkowski Preclinical Development and First-In-Human Testing of GRNCM1 in Advanced Heart Failure $0
Total:
$6,405,771.00
Icon for xls export